Invida To Handle Roche PC Portfolio in Korea

Invida Group Pte Ltd. has entered into a partnership agreement with Roche for the commercialization and marketing of Roche’s primary care portfolio throughout Korea. Invida’s commercialization of these products and will allow Roche to focus on its specialty care portfolio in Korea.

Invida will manage all of the marketing and sales activities for Roche’s primary care products, including Xenical and Roaccutane, as well as products from Roche’s CNS portfolio, including Madopar for the treatment of Parkinson’s disease and Rivotril for epilepsy and Valium. Roche Korea has restructured for 2011 as part of its recently announced Operational Excellence Program.

Mark Brown, general manager, Invida Korea, commented, “We are excited to partner with Roche and provide them with the vital infrastructure to promote these products in the Korean market. In developing our agreement with Roche, we were very conscious of creating an alliance structure that would work within the Korean market and provide outstanding products for patients, while benefiting both companies. Roche’s primary care portfolio is one that will benefit greatly from the additional promotion that Invida will invest in it, and allow Roche to focus on developing other core areas of business.”

Svend Petersen, general manager, Roche Korea, said, “Our partnership with Invida is critical to ensure our success in further penetrating the Korean market. In working with Invida and utilizing their strong infrastructure and proven sales and marketing methodologies, we will be able to gain rapid market access for these products and reach primary care physicians throughout the region. This alliance will support our business goals by allowing us to shift resources and focus on our specialty care portfolio. We plan to continue to bring innovative products into Korea that will meet the needs of Korean patients.”